Vaspin in newly and previously diagnosed Chinese type 2 diabetic females: a case-control study

Background: Visceral adipose tissue-derived serine protease inhibitor (vaspin) is a novel adipocytokine. Several studies have indicated that vaspin may exert an important role in the development of metabolic disorders.

Objective: Evaluate serum vaspin and its relation to clinical parameters in newly and previously diagnosed Chinese type 2 diabetes mellitus (T2DM) females as a case-control study.

Materials and methods: One hundred twenty female participants (newly and previously diagnosed T2DM patients) were recruited from an affiliated hospital of Harbin Medical University. Sixty healthy female volunteers from various communities were included as controls. Anthropometric parameters, serum fasting blood glucose, fasting insulin, lipid profile, HbA1c, and vaspin were measured in each participant.

Results: Serum vaspin levels were significantly lower in previously diagnosed T2DM patients (0.51±0.29 ng/mL) than in newly diagnosed T2DM patients (0.62±0.28 ng/mL) and healthy controls (0.69±0.31 ng/mL). However, there was no difference in serum vaspin between newly diagnosed T2DM patients and healthy controls. In multiple linear regression analysis, serum vaspin was significantly and positively associated with HbA1c in both newly and previously diagnosed T2DM patients, negatively associated with homeostasis model assessment of insulin resistance in previously diagnosed patients, and positively correlated with age and body mass index in healthy controls.

Conclusion: Serum vaspin was significantly lower in previously diagnosed T2DM patients than in newly diagnosed T2DM patients and healthy controls. Serum vaspin might be a predictor of poor glucose control and insulin resistance in T2DM.